Struggling for supply

alert shortage warning
Shortage notice issued for multiple presentations of arthritis treatment The Therapeutic Goods Administration (TGA) has issued a warning regarding shortages of multiple presentations of tocilizumab (Actemra). Roche, the sponsor of tocilizumab (Actemra), notified the TGA on 21 July, saying the shortage was due to global demand in response to the COVID-19 pandemic. In its notice,

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous ‘We all hope he gets taken care of.’
Next Pharmacy jab advice ‘puts people at risk,’ says doc